NEW YORK, Dec. 29, 2010 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:
E7: The Outlook for Pharmaceuticals to 2012
http://www.reportlinker.com/p0192576/E7-The-Outlook-for-Pharmaceuticals-to-2012.html
E7: The Outlook for Pharmaceuticals to 2012 is a new collection
of management reports from Espicom Business Intelligence. Each
report provides an individual and highly-detailed analysis of each
market, looking at the key regulatory, political, economic and
corporate developments in the wider context of market structure,
service and access. The reports are available individually or as a
discounted collection.
The E7 economies represent increasing opportunities for
pharmaceutical companies constrained by maturing markets in the
west.
Less reliance on mature markets
A report from PricewaterhouseCoopers (Pharma 2020: The vision:
Which path will you take?) highlighted the dangers for the
pharmaceutical industry of relying on existing mature markets such
as the USA in the period to 2020. Pressures on pricing and greater
payor influence will reduce the relative profitability of the USA,
meaning that the industry will do well to look elsewhere for
growth.
Huge potential in E7 markets
The emerging ‘E7’ countries represent the best prospect for
growth. The potential of these countries is huge: they have a
combined population of over three billion people, and their
economies are recovering from the economic downturn. One
consequence of this increasing wealth is a growing financial
capacity to treat previously unmet health needs. Another is
increasing incidence of ‘affluence’ diseases such as
diabetes,
‘/>”/>
